Table 1 Baseline characteristics of both cohorts
CRIC (N = 3939) | CKD-JAC (N = 2966) | |
|---|---|---|
Males, N (%) | 2161 (55) | 1841 (62) |
Age, years | 58.2 ± 11 | 60.3 ± 11.6 |
Race, N (%) | ||
White | 1638 (41.6) | |
Black | 1650 (41.9) | |
Hispanic | 497 (12.6) | |
Asians | 106 (2.7) | 2966 (100) |
Others | 46 (1.2) | |
Income, N (%) | ||
Lowest | 1240 (37.3) | 456 (24.7) |
Middle | 958 (28.8) | 507 (27.4) |
Mod. High | 734 (22.1) | 433 (23.4) |
Highest | 392 (11.8) | 453 (24.5) |
Education, N (%) | ||
Lowest | 828 (21) | 437 (17.6) |
Middle | 741 (18.8) | 996 (40) |
Mod. High | 1146 (29.1) | 419 (16.8) |
Highest | 1223 (31.1) | 635 (25.5) |
BMI, kg/m2 | 32.1 ± 7.8 | 23.5 ± 3.8 |
eGFR, mL/min/1.73m2 | 42.8 ± 13.5 | 28.9 ± 12.3 |
UACR, mg/gCr | 51.9 [8.7–458.8] | 485.9 [113.3–1312.7] |
Diabetes, N (%) | 1907 (48) | 1117 (38) |
Hypertension, N (%) | 3633 (93) | 2772 (94) |
Atrial fibrillation, N (%) | 666 (17) | 61 (2) |
Systolic blood pressure, mmHg | 128.5 ± 22.2 | 131.7 ± 18.6 |
Diastolic blood pressure, mmHg | 71.5 ± 12.8 | 76.3 ± 11.8 |
Anti-hypertensive drugs, N (%) | ||
ACEi/ARB | 2688 (69) | 2427 (82) |
Ca channel blockers | 1584 (41) | 1646 (55) |
β-blockers | 1930 (49) | 599 (20) |
α-blockers | 567 (14) | 408 (14) |
Diuretics | 2331 (60) | 909 (31) |
CVD historya, N (%) | ||
Any CVD history | 1316 (33) | 726 (24) |
CAD | 862 (22) | 374 (13) |
CHF | 382 (10) | 132 (4) |
Stroke | 392 (10) | 295 (10) |
PAD | 262 (7) | 111 (4) |
